Patents by Inventor Ian STRUTT
Ian STRUTT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12180186Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.Type: GrantFiled: August 11, 2023Date of Patent: December 31, 2024Assignee: Corcept Therapeutics IncorporatedInventors: Hazel Hunt, Lorna Duffy, Ian Strutt, Morgan Jouanneau, Thomas Hornsby, Mark Mills, Andrew William Phillips, Jon-Paul Ward
-
Patent number: 12012392Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: November 9, 2018Date of Patent: June 18, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Ian Strutt
-
Publication number: 20240150320Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.Type: ApplicationFiled: August 11, 2023Publication date: May 9, 2024Inventors: Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
-
Patent number: 11787780Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.Type: GrantFiled: June 21, 2021Date of Patent: October 17, 2023Assignee: Corcept Therapeutics IncorporatedInventors: Hazel Hunt, Lorna Duffy, Ian Strutt, Morgan Jouanneau, Thomas Hornsby, Mark Mills, Andrew William Phillips, Jon-Paul Ward
-
Patent number: 11613542Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: August 15, 2018Date of Patent: March 28, 2023Assignee: Inflazome LimitedInventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt, Jokin Carrillo Arregui
-
Publication number: 20230032612Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.Type: ApplicationFiled: June 21, 2021Publication date: February 2, 2023Inventors: Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
-
Patent number: 11542255Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: August 15, 2018Date of Patent: January 3, 2023Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt
-
Publication number: 20220106289Abstract: The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.Type: ApplicationFiled: November 22, 2019Publication date: April 7, 2022Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Ian STRUTT, Diana CASTAGNA, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG
-
Publication number: 20210130359Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 15, 2018Publication date: May 6, 2021Applicant: Inflazome LimitedInventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT, Jokin CARRILLO ARREGUI
-
Publication number: 20210130329Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 15, 2018Publication date: May 6, 2021Applicant: Inflazome LimitedInventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT
-
Publication number: 20200361895Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; and R2 is a cyclic group substituted at the ?-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the ? ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 15, 2018Publication date: November 19, 2020Applicant: Inflazome LimitedInventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT
-
Publication number: 20200317637Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: November 9, 2018Publication date: October 8, 2020Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Ian STRUTT